Enabling Protein Degradation Drug Discovery

*Purity of all products >95% unless otherwise stated
  • Name
    Catalogue Number
    Size
    Price
    Add to Basket
  • Name:
    UBE2G1(Ubc7) [untagged]
    Catalogue Number:
    62-0028-100
    Size:
    100 µg
    Price:
    £325
    Add To Basket
  • Species
    Human
  • Source
    E. coli expression
  • Quantity
    100 μg
  • Storage
    -70°C
  • Concentration
    1 mg/ml
  • Formulation
    50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol
  • Molecular Weight
    ~21 kDa
  • Stability
    12 months at -70°C; aliquot as required
  • Protein Sequence
    Accession number: NP_003333. For full protein sequence information download the Certificate of Analysis pdf.
  • QA; Protein Identification
    Confirmed by mass spectrometry.
  • QA; Activity
    E2-Ubiquitin Thioester Loading Assay: The activity of UBE2G1 was validated by loading E1 UBE1 activated ubiquitin onto the active cysteine of the UBE2G1 E2 enzyme via a transthiolation reaction. Incubation of the UBE1 and UBE2G1 enzymes in the presence of ubiquitin and ATP at 30 ̊C was compared at two time points, T0 and T10 minutes. Sensitivity of the ubiquitin/UBE2G1 thioester bond to the reducing agent DTT was confirmed.    

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including regulated and targeted proteasomal degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). UBE2G1 is a member of the E2 conjugating enzyme family and cloning of the human gene was first described by Watanabe et al. (1996). UBE2G1 shares 74% sequence identity with UBC7 from C. elegans and a high degree of homology with UBC7 from other species. Expression of UBE2G1 and a helix-loop-helix transcription factor and member of the MYC/MAX superfamily (ROX/MNT) is decreased in medullablastoma tumours. Haploinsufficiency of the human 17p13.3 region is associated with 35% to 50% of medullablastomas, indicating the presence of one or more tumour suppressor genes which have not yet been identified (Cvekl et al., 2004).

References:

Cvekl A, Jr., Zavadil J, Birshtein BK, Grotzer MA, Cvekl A (2004) Analysis of transcripts from 17p13.3 in medulloblastoma suggests ROX/MNT as a potential tumour suppressor gene. Eur J Cancer 40, 2525-32.

Watanabe TK, Kawai A, Fujiwara T, Maekawa H, Hirai Y, Nakamura Y, Takahashi E (1996) Molecular cloning of UBE2G, encoding a human skeletal muscle-specific ubiquitin-conjugating enzyme homologous to UBC7 of C. elegans. Cytogenet Cell Genet 74, 146-8.